Silence Therapeutics plc (SLN): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of SLN were reported in the last 12 months. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Silence Therapeutics
From the latest filingsOverall: more buying than selling. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns SLN
69 funds and institutions reported SLN shares worth $249M at the end of Q2 2026, about 16% of the company. The largest holder is Siren, L.L.C. with 2.3%.
Funds and institutions (13F) 16%Everyone else 84%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Siren, L.L.C. | 3.31M | 2.34% | $36.4M | +14% |
| TCG Crossover Management, LLC | 3.03M | 2.14% | $33.3M | No change |
| Nantahala Capital Management, LLC | 2.69M | 1.90% | $29.6M | +25% |
| Redmile Group, LLC | 2.16M | 1.53% | $23.8M | No change |
| Citadel Advisors LLC | 1.33M | 0.94% | $14.6M | +8% |
| Nextech Invest Ltd. | 952,400 | 0.67% | $10.5M | No change |
| Millennium Management LLC | 909,279 | 0.64% | $10M | -15% |
| Tetragon Partners GP Ltd | 764,256 | 0.54% | $8.4M | +21% |
| Soleus Capital Management, L.P. | 630,000 | 0.44% | $6.9M | New |
| Balyasny Asset Management L.P. | 610,980 | 0.43% | $6.7M | New |
| 5AM Venture Management, LLC | 476,200 | 0.34% | $5.2M | No change |
| Great Point Partners LLC | 450,000 | 0.32% | $4.9M | -56% |
| Morgan Stanley | 403,172 | 0.28% | $4.4M | +516% |
| Ameriprise Financial Inc | 370,052 | 0.26% | $4.1M | New |
| Jane Street Group, LLC | 369,151 | 0.26% | $4.1M | +266% |
| ADAR1 Capital Management, LLC | 338,373 | 0.24% | $3.7M | +97% |
| SummitTX Capital, L.P. | 326,648 | 0.23% | $3.6M | New |
| Schonfeld Strategic Advisors LLC | 269,348 | 0.19% | $3M | New |
| UBS Group AG | 243,152 | 0.17% | $2.7M | -2% |
| BlackRock, Inc. | 219,917 | 0.16% | $2.4M | +7% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No SLN insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SLN short interest
Low short interest. 1.3% of SLN shares are sold short: about 1 share in 77. Over the last 12 reports the number of shares short went up 22%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.42M SLN shares were sold short, 1.3% of the shares outstanding, down 17.4% from the report before. At the average daily volume of 9.22M shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.42M | 1.30% | -17% | 9.22M | 1.0 |
| Oct 15, 2026 | 2.93M | 1.57% | +15% | 1.27M | 2.3 |
| Sep 30, 2026 | 2.54M | 1.36% | +17% | 827,101 | 3.1 |
| Sep 15, 2026 | 2.18M | 1.54% | -11% | 861,199 | 2.5 |
| Aug 31, 2026 | 2.44M | 1.72% | +0% | 695,204 | 3.5 |
| Aug 14, 2026 | 2.43M | 1.72% | +32% | 2.89M | 1.0 |
| Jul 31, 2026 | 1.84M | 1.30% | +17% | 560,270 | 3.3 |
| Jul 15, 2026 | 1.57M | 1.11% | -9% | 499,806 | 3.1 |
| Jun 30, 2026 | 1.73M | 1.22% | -16% | 772,826 | 2.2 |
| Jun 15, 2026 | 2.07M | 1.46% | +0% | 241,168 | 8.6 |
| May 29, 2026 | 2.06M | 1.45% | +4% | 225,140 | 9.1 |
| May 15, 2026 | 1.99M | 1.40% | -8% | 181,913 | 10.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Silence Therapeutics company events
Silence Therapeutics filed 14 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Oct 19, 2026.
- Oct 19, 2026AgreementSilence Therapeutics plc, a public limited company incorporated in England and Wales, entered into a transaction agreement with Merck KGaA, Darmstadt, Germany, a German corporation with general partners. Filing
- Aug 12, 2026AgreementSilence Therapeutics plc entered into an underwriting agreement with Jefferies LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters set forth therein, to issue and sell 12,962,963 American Depositary Shares of the Company, each representing three ordinary shares, nominal… Filing
- Aug 10, 2026AnnouncementThe Company issued a press release announcing positive topline results from the Phase 2 SANRECO trial, a 36-week, randomized, double-blind, placebo-controlled portion of the Phase 2 trial evaluating divesiran (6 mg/kg) administered subcutaneously every six weeks or every twelve weeks met its… Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jul 16, 2026LeadershipAmended an earlier report. Of the Current Report on Form 8-K filed on December 15, 2025 to disclose information regarding material modifications to a material compensatory plan, contract or arrangement as to which a named executive officer of the registrant participates that were effected pursuant to an agreement entered… Filing
- Jun 23, 2026AnnouncementShared information with investors. Filing
- Jun 16, 2026VoteReported shareholder vote results. Filing
- Jun 11, 2026AnnouncementSilence Therapeutics plc issued a press release highlighting follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6, in 21 phlebotomy-dependent patients with polycythemia vera (PV) presented at the European Hematology… Filing
- May 18, 2026AgreementSilence Therapeutics plc entered into an Open Market Sale Agreement SM with Jefferies LLC. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 5, 2026ResultsReleased financial results. Filing
- Dec 22, 2025LeadershipAmended an earlier report. Update Regarding Principal Executive Officer Compensation Arrangement As previously disclosed in the Original Report, Iain Ross, Chairman of the Board, was appointed as interim principal executive officer of the Company, effective December 14, 2025. Filing
- Dec 22, 2025LeadershipThe Board of Directors of Silence Therapeutics plc appointed Rhonda Hellums, the Company’s Executive Vice President and Chief Financial Officer, to the Board, effectively immediately. Filing
- Dec 15, 2025LeadershipSilence Therapeutics plc announced that Craig Tooman, who has served as the Company’s President, Chief Executive Officer and a member of the Company’s Board of Directors since 2022, agreed by mutual consent to end his employment with the Company and step down from the Board effective December 14… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Silence Therapeutics financials
Famous investors that hold SLN
6 of the 50 well-known investors we track reported holding SLN in their latest 13F filing. The largest position is Ken Griffin's, worth $30.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.83M | $30.9M | 0.0% | +113% |
| Israel Englander · Millennium Management | Q3 2026 | 1.45M | $15.9M | 0.0% | +60% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 152,200 | $1.7M | 0.0% | +799% |
| George Soros · Soros Fund Management | Q3 2026 | 100,000 | $1.1M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 44,252 | $484K | 0.0% | New |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 40,192 | $439K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named SLN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | TCG Crossover GP I, LLC | 13G/A | 3.9% |
| Nov 16, 2026 | TCG Crossover GP I, LLC | 13G/A | 3.9% |
| Nov 12, 2026 | Invus Public Equities, L.P. | 13G/A | 4.1% |
| Nov 12, 2026 | Invus Public Equities, L.P. | 13G/A | 4.1% |
| Nov 5, 2026 | FMR LLC | 13G | 7.1% |
| Nov 5, 2026 | FMR LLC | 13G | 7.1% |
| Oct 13, 2026 | Tetragon Financial Group Limited | 13G | 5.2% |
| Oct 13, 2026 | Tetragon Financial Group Limited | 13G | 5.2% |
| Oct 13, 2026 | Tetragon Financial Group Limited | 13G/A | 5.3% |
| Oct 13, 2026 | Tetragon Financial Group Limited | 13G/A | 5.3% |
Questions about Silence Therapeutics plc (SLN) stock
Who owns the most SLN stock?
The largest reported owner of Silence Therapeutics plc (SLN) is Siren, L.L.C., with 2.3% of the company. In total, 69 funds and institutions reported holding SLN at the end of Q2 2026, together about 16% of the shares. See the largest owners.
Are SLN insiders buying or selling?
No SLN insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in SLN?
As of Oct 30, 2026, 2.42M SLN shares were sold short, 1.3% of the shares outstanding, down 17.4% from the report before. At the average daily volume of 9.22M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold SLN?
6 of the 50 well-known investors we track reported SLN in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $30.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.